Sahajanand Medical Technologies, India Receives CE Mark on Two Sirolimus Eluting Coronary Stents

Published: Jul 01, 2011

The CE approval for Supralimus® and Supralimus-Core® brings the company the distinction of being the first in the world to have CE approval for both Sirolimus and Paclitaxel -eluting coronary stents and in total three CE approved drug eluting stents. “The CE mark for Supralimus® and Supralimus-Core® is a significant accomplishment that substantiates our product’s excellent clinical outcomes. This further confirms our commitment to providing patients and clinicians new treatment options for coronary artery disease.” shared Dhirajlal Kotadia-CEO of Sahajanand, “The excellent flexibility, highly deliverable system and proven safety and efficacy of Sirolimus with the biodegradable polymers make our stents an excellent choice for a variety of patients” he added.

Back to news